Tuesday, June 27, 2017
(40-minute seminar, 15-minute Q&A)
Jane Lamerdin, Ph.D.
PBMC effector cells have inherent donor variability, reducing their consistency and reproducibility in lot release assays. Antibody-Dependent Cell Cytotoxicity (ADCC) assays that measure cell death often have low signal to background ratios and suffer from this donor variability of the PBMCs.
Learn how the KILR CD16 Effector Cells ensure assay reproducibility with higher signal to background ratios, without worrying about donor variability.
What will be covered?
- Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
- Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
- Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells
Who should attend?
- Assay Development Scientists focused on biologics, biosimilars, biobetters, or immunotherapeutics
- Scientists developing and validating cytotoxicity assays to measure target cells death